John P.H. Wilding, DM; Vincent Woo, MD; Norman G. Soler, MD, PhD; Andrea Pahor, MD; Jennifer Sugg, MS; Katja Rohwedder, MD; Shamik Parikh, MD; for the Dapagliflozin 006 Study Group
Persons with type 2 diabetes may have inadequate glycemic control despite high insulin doses, and increasing insulin doses can cause adverse effects. Dapagliflozin inhibits renal absorption of glucose, and clinical trials have shown that it improves glycemic control alone or with metformin. In this 24-week randomized trial, adding dapagliflozin to insulin therapy for inadequately controlled type 2 diabetes improved hemoglobin A1c and weight loss compared with placebo. However, this study could not evaluate long-term effectiveness and safety concerns that have hindered approval of this drug by the U.S. Food and Drug Administration.
Ann Intern Med. 2012;156(6):405-415. doi:10.7326/0003-4819-156-6-201203200-00003
Judith A. Long, MD; Erica C. Jahnle, BA; Diane M. Richardson, PhD; George Loewenstein, PhD; Kevin G. Volpp, MD, PhD
Clinic-based care management interventions have been shown to help patients with diabetes improve glucose control but are expensive. This randomized, controlled trial compared peer mentoring, a modest financial incentive, or usual care in African American veterans, mostly men, with poor diabetes control. Hemoglobin A1c levels decreased more in the peer mentoring group than in the usual care and financial incentive groups. A peer mentorship model could be a scalable approach to improving control in this population and reducing disparities in diabetic outcomes.
Ann Intern Med. 2012;156(6):416-424. doi:10.7326/0003-4819-156-6-201203200-00004
J. Christopher Gallagher, MD; Adarsh Sai, MBBS; Thomas Templin, MD; Lynette Smith, MS
Vitamin D supplementation is widely recommended to patients, but the optimal dose is debated. This trial randomly assigned postmenopausal white women with vitamin D insufficiency to receive either placebo or increasing doses of vitamin D3, as well as calcium supplements. An 800-IU/d dosage of vitamin D3 achieved a serum 25-hydroxyvitamin D level greater than 50 nmol/L in 97.5% of women. A model predicted the same response with 600 IU/d, although this dosage was not studied.
Ann Intern Med. 2012;156(6):425-437. doi:10.7326/0003-4819-156-6-201203200-00005
Maryam Kavousi, MD, MSc; Suzette Elias-Smale, MD, PhD; Joost H.W. Rutten, MD, PhD; Maarten J.G. Leening, MD, MSc; Rozemarijn Vliegenthart, MD, PhD; Germaine C. Verwoert, MSc; Gabriel P. Krestin, MD, PhD; Matthijs Oudkerk, MD, PhD; Moniek P.M. de Maat, PhD; Frank W.G. Leebeek, PhD; Francesco U.S. Mattace-Raso, MD, PhD; Jan Lindemans, PhD; Albert Hofman, MD, PhD; Ewout W. Steyerberg, PhD; Aad van der Lugt, MD, PhD; Anton H. van den Meiracker, MD, PhD; Jacqueline C.M. Witteman, PhD
Optimizing coronary heart disease risk prediction can help target preventive interventions. This study examined whether the addition of newer markers (N-terminal fragment of prohormone B-type natriuretic peptide [NT-proBNP], von Willebrand factor antigen, fibrinogen, chronic kidney disease, leukocyte count, C-reactive protein, homocysteine, uric acid, coronary artery calcium [CAC] score, carotid intima–media thickness, peripheral artery disease, and pulse wave velocity) to the Framingham risk score improved prediction in 5933 asymptomatic patients. Only CAC score and possibly NT-proBNP resulted in clinically meaningful improvements. Despite these favorable results for CAC score, it is expensive and exposes individuals to radiation, so its use for coronary risk assessment requires further evaluation.
Ann Intern Med. 2012;156(6):438-444. doi:10.7326/0003-4819-156-6-201203200-00006
Suetonia C. Palmer, MB ChB, PhD; Lucia Di Micco, MD; Mona Razavian, MB BS; Jonathan C. Craig, MB ChB, DCh, MM, PhD; Vlado Perkovic, MB BS, PhD; Fabio Pellegrini, MSc; Massimiliano Copetti, MSc, PhD; Giusi Graziano, MSc; Gianni Tognoni, MD; Meg Jardine, MB BS, PhD; Angela Webster, MB BS, PhD; Antonio Nicolucci, MD; Sophia Zoungas, MD, PhD; Giovanni F.M. Strippoli, MD, PhD, MPH, MM
Antiplatelet agents are given for cardiovascular prevention to patients with chronic kidney disease (CKD). This review found that glycoprotein IIb/IIIa inhibitors or clopidogrel increased major bleeding but had little or no effect on myocardial infarction, death, or coronary revascularization in patients with CKD who had acute coronary syndromes or were undergoing percutaneous coronary revascularization. In other patients with CKD who had or were at risk for cardiovascular disease, antiplatelet regimens increased minor bleeding, reduced myocardial infarction, and had uncertain effects on mortality. However, evidence was weak in quality and derived primarily from subgroup analysis of trials.
Ann Intern Med. 2012;156(6):445-459. doi:10.7326/0003-4819-156-6-201203200-00007
Thomas V. Inglesby, MD
A recently engineered H5N1 virus that is transmissible between ferrets may also be transmissible between humans. If the virus were to escape the laboratory, it could endanger the lives of hundreds of millions of persons. The author of this commentary discusses why the possible benefits of this research do not justify taking such risk and how the principle of free and open exchange of scientific information has come into a rare moment of conflict with that of “first, do no harm.”
Ann Intern Med. 2012;156(6):460-462. doi:10.7326/0003-4819-156-6-201203200-00387
Andrew T. Pavia, MD
The controversy surrounding the newly engineered H5N1 influenza virus escalated when the National Science Advisory Board for Biosecurity recommended that the work be published but recommended significant voluntary redactions. The author of this commentary discusses the polarizing responses to this action and the research and believes that the knowledge gained by these and future experiments under appropriate safeguards is likely to allow critical understanding of influenza transmission and virulence.
Ann Intern Med. 2012;156(6):463-465. doi:10.7326/0003-4819-156-6-201203200-00386
Steven A. Smith, MD
Dapagliflozin offers a novel, insulin-independent mechanism of action for diabetes treatment. In this issue, Wilding and colleagues report on the effectiveness and safety of adding dapagliflozin to insulin therapy or insulin therapy with other oral hyperglycemic agents. The editorialist discusses the findings, as well as the U.S. Food and Drug Administration deliberation regarding approval of dapagliflozin.
Ann Intern Med. 2012;156(6):466-467. doi:10.7326/0003-4819-156-6-201203200-00012
Mark A. Hlatky, MD
In this issue, Kavousi and colleagues assessed 12 novel risk markers for coronary heart disease. The CAC score added the most to the Framingham risk score, and NT-proBNP level was a close second. The editorialist discusses the study and urges that strong evidence is needed before these new risk markers are incorporated into routine clinical practice.
Ann Intern Med. 2012;156(6):468-469. doi:10.7326/0003-4819-156-6-201203200-00013
Andreas Thyssen, BS
I debated whether what I was about to ask would be laughed off or viewed as another naive question from a medical student along for his first ambulance ride. I decided to risk it and turned back toward the paramedic. “How do you deliver a baby when your legs are handcuffed to the bed?”
Ann Intern Med. 2012;156(6):470. doi:10.7326/0003-4819-156-6-201203200-00014
Sondra S. Crosby, MD
Stepping off the plane in an unfamiliar country, jet-lagged, and unable to speak a word of the native language, I was a little disoriented. I met my patient at the hotel in less than an hour of my arrival. I could tell he was apprehensive. This unique and complicated situation demanded creative and unorthodox measures.
Ann Intern Med. 2012;156(6):471-472. doi:10.7326/0003-4819-156-6-201203200-00015
Ann Intern Med. 2012;156(6):473. doi:10.7326/0003-4819-156-6-201203200-00017
Ann Intern Med. 2012;156(6):473. doi:10.7326/0003-4819-156-6-201203200-00018
Ann Intern Med. 2012;156(6):473-474. doi:10.7326/0003-4819-156-6-201203200-00019
Ann Intern Med. 2012;156(6):474-475. doi:10.7326/0003-4819-156-6-201203200-00020
Ann Intern Med. 2012;156(6):475-476. doi:10.7326/0003-4819-156-6-201203200-00021
Risa Denenberg, NP, MSN
Ann Intern Med. 2012;156(6):462. doi:10.7326/0003-4819-156-6-201203200-00010
Joseph Gascho, MD
Ann Intern Med. 2012;156(6):472. doi:10.7326/0003-4819-156-6-201203200-00016
Belinda Kiely, MD; Martin Stockler, MD
Ann Intern Med. 2012;156(6):JC2-4. doi:10.7326/0003-4819-156-6-201202210-02004
Santiago Moreno, MD
Ann Intern Med. 2012;156(6):JC3-2. doi:10.7326/0003-4819-156-6-201202210-02002
Francesco Dentali, MD
Ann Intern Med. 2012;156(6):JC3-3. doi:10.7326/0003-4819-156-6-201202210-02003
Edward P. Havranek, MD
Ann Intern Med. 2012;156(6):JC3-5. doi:10.7326/0003-4819-156-6-201202210-02005
David C. Anderson, MD
Ann Intern Med. 2012;156(6):JC3-6. doi:10.7326/0003-4819-156-6-201202210-02006
Joram S. Seggev, MD, FAAAAI, FACAAI, FACP
Ann Intern Med. 2012;156(6):JC3-7. doi:10.7326/0003-4819-156-6-201202210-02007
Yves Lacasse, MD, MSc, FRCPC
Ann Intern Med. 2012;156(6):JC3-8. doi:10.7326/0003-4819-156-6-201202210-02008
Mark J. Alberts, MD
Ann Intern Med. 2012;156(6):JC3-9. doi:10.7326/0003-4819-156-6-201202210-02009
Alka M. Kanaya, MD
Ann Intern Med. 2012;156(6):JC3-10. doi:10.7326/0003-4819-156-6-201202210-02010
Ann Intern Med. 2012;156(6):JC3-11. doi:10.7326/0003-4819-156-6-201202210-02011
David H. Hickam, MD, MPH
Ann Intern Med. 2012;156(6):JC3-12. doi:10.7326/0003-4819-156-6-201202210-02012
Steven M. Opal, MD
Ann Intern Med. 2012;156(6):JC3-13. doi:10.7326/0003-4819-156-6-201202210-02013
Ann Intern Med. 2012;156(6):I-44. doi:10.7326/0003-4819-156-6-201203200-00001
Ann Intern Med. 2012;156(6):I-50. doi:10.7326/0003-4819-156-6-201203200-00002
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only